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ABSTRACT 
Serological analysis of a recombinant cDNA expression library (SEREX) derived from 
two lung adenocarcinoma cancer cell lines using autologous sera led to the isolation of 41 
positive cDNA clones comprising 28 different antigens. They coded for a variety of 
nuclear and cytoplasmic proteins. Among the antigens, nucleoporin 107 (NUP107) was 
isolated most frequently (5 of 41 clones). The second most frequently isolated antigen 
was coded for by C21orf58 (4 of 41 clones). During serological analysis of selected 
antigens based on their reactivity to sera from normal individuals and lung cancer patients, 
none of the antigens showed a cancer-restricted recognition pattern. However, 5 genes 
including NUP107 showed higher expression when we examined the changes in gene 
expression in 5 different adenocarcinoma cell lines, including those used in SEREX, 
compared with their levels in normal lung tissues by cDNA microarray analysis. On the 
other hand, the expression levels of 5 genes including C21orf58 were down regulated in 
all adenocarcinoma cell lines. This SEREX study combining comprehensive gene 
expression assays has added to the growing list of lung cancer antigens, which may aid 
the development of diagnostic and immunotherapeutic reagents for patients with lung 
cancer. 
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1. Introduction 
   Lung cancer is one of the leading causes of cancer death, and its 5-year survival rate is 
poor, even in the early stages [1, 2]. Recent progress in tumor immunology based on the 
molecular identification of tumor antigens has suggested that immunotherapy has 
potential as a promising treatment for lung cancer. 
   Serological analysis of recombinant cDNA expression libraries (SEREX) was 
developed to combine serological analysis with antigen cloning techniques in order to 
identify human tumor antigens that eliciting high-titer IgG antibodies [3, 4]. SEREX has 
contributed greatly to our understanding of the humoral immune response to cancer [5]. It 
has led to the identification of a variety of tumor antigens, including cancer/testis (CT) 
antigens [6, 7], mutational antigens [8], over-expressed antigens [9, 10], differentiation 
antigens [6, 11], splice-variant antigens [12], and viral antigens [13]. 
     Using the SEREX approach in lung cancer, several previously unknown lung cancer 
antigens have been identified and characterized [14-17]. In our previous studies, we 
isolated a CT antigen, XAGE-1, in lung adenocarcinoma by SEREX analysis.  In the 
XAGE-1 transcripts, XAGE-1b was the dominant antigen and was found to be highly 
immunogenic for antibody production in lung adenocarcinoma patients [18, 19]. In the 
present study, we applied the SEREX methodology to 2 lung adenocarcinoma cell lines in 
combination with comprehensive gene expression assays in order to add to the repertoire 
of lung cancer antigens. 
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2. Materials and Methods 
2.1. Tissues, cell lines, and sera  
   Tumor specimens were surgically obtained from patients at Kawasaki Medical 
University Hospital. Lung cancer and adjacent normal lung tissues were obtained in the 
same samples from 5 specimens. OU-LU-6, -11, -14, -17, and -26 were lung cancer cell 
lines established from the pleural effusions of male patients with lung adenocarcinoma. 
Sera were obtained from 32 lung cancer patients and 27 healthy donors. Written informed 
consent was obtained from all patients and healthy donors involved in our study in 
accordance with the university guidelines. 
 
2.2. Preparation of the cDNA library from the lung cancer cell lines 
   mRNA was purified from the two lung adenocarcinoma cell lines OU-LU-11 and 
OU-LU-17 using a Quick Prep mRNA Purification Kit (Amersham Pharmacia, 
Piscataway, NJ). Then, a cDNA expression library was prepared in a ZAP Express vector 
using a cDNA library kit (Stratagene, La Jolla, CA). 
 
2.3. Immunoscreening of cDNA libraries 
   cDNA expression libraries of lung cancer cell lines were screened with autologous 
patient sera. The screening procedure was described previously [18, 20]. In brief, serum 
samples that had been diluted 1:10 were preabsorbed with lysate from Escherichia coli 
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Y1090/Y1089 and coupled to Sepharose 4B (BioDynamics Lab Inc., Tokyo, Japan).  
Recombinant phages (approximately 4,000 pfu) on agar in a plastic dish (140 mm 
diameter) were amplified for 8 hr and then transferred to 135 mm diameter nitrocellulose 
membranes (Schleicher & Schuell, Dassel, Germany) for 15 hr at 37°C.   The 
membranes were then blocked with 5% non-fat milk and pre-screened by incubation with 
peroxidase-conjugated Fc fragment-specific goat anti-human IgG (Jackson 
ImmunoResearch, West Grove, PA, USA) (1:2,000 dilution) for 1 hr at room temperature. 
Color was developed using 3, 3’ diaminobenzidine (Sigma, St. Louis, MO, USA), and 
IgG-encoding clones were marked so that they could be excluded from subsequent 
examinations. The membranes were then incubated overnight at room temperature with 
the preabsorbed serum diluted to 1:200. The membranes were incubated with 
peroxidase-conjugated Fc fragment-specific goat anti-human IgG (Jackson 
ImmunoResearch) (1:2,000 dilution) for 1 hr at room temperature and color was 
developed. Positive clones were collected and subcloned to monoclonality by 2nd and 3rd 
screenings using 82 and 47 mm diameter membranes, respectively. A randomly chosen 
negative clone was included in each assay as a negative control.  Phage plaque assays 
were performed to test the reactivity of sera (1:200 dilution) from healthy donors and lung 
cancer patients against SEREX-defined clones. Exponentially growing E. coli XL-1 Blue 
MRF’ were infected with 20-30 pfu of cloned phages encoding individual 
SEREX-defined antigens and then mixed with 0.7% NZY agarose/2.5mM IPTG. 
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Bacterial suspensions (100 l) containing cloned phages encoding SEREX-antigens were 
then plated on 1.5% NZY agar in plastic dishes (140 mm diameter), amplified for 8 hr, 
and transferred to nitrocellulose membranes for 15 hr at 37°C. Color was developed as 
described above. 
 
2.4. Sequence analysis of reacted clones 
   The clones that reacted positively were subcloned to monoclonality, purified, and 
excised in vivo to pBK-CMV plasmid forms (Stratagene). The plasmid DNA was 
prepared using the Quantum Prep Plasmid Miniprep Kit (Bio-Rad, Hercules, CA).  The 
nucleotide sequences of the cDNA inserts were determined using ABI 3130x1 Genetic 
Analyzer (Applied Biosystems Foster City, CA), and sequence alignment was performed 
with BLAST software and sequences in the GenBank database. 
 
2.5. Total RNA isolation and cDNA synthesis 
   Total RNA was isolated from the tumor tissues using an RNeasy Mini Kit (Qiagen, 
Hilden, Germany). Total RNA from normal tissues was obtained commercially (BD 
Bioscience Clontech, Palo Alto, CA, USA). The RNA (2 μg) was reverse-transcribed into 
single-strand cDNA using Moloney murine leukemia virus reverse transcriptase 
(Ready-To-Go You-Prime First-Strand Beads, GE Healthcare, Buckinghamshire, UK) 
and oligo(DT)15 as a primer. The cDNA samples were tested for integrity by amplification 
of G3PDH in a 30-cycle reaction. 
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2.6. Gene expression microarrays 
   Gene expression was examined using Agilent Human 1A oligomicroarrays containing 
60-mer DNA probes in a 22K format (Agilent Technologies, Palo Alto, CA).   Of 19,061 
spots, 18,086 are non-controls, and there are 17,086 unique transcript sequences from 
15,989 unique human genes. Five hundred nanogram of total RNA from lung 
adenocarcinoma cell lines for the test samples and normal lung tissue for the reference 
samples were used to synthesize labeled cRNA (Low RNA Input Linear Amp Kit, Agilent 
Technologies) in the presence of cyanine 3-dCTP and cyanine 5-dCTP (Perkin-Elmer 
Life Sciences, Boston, MA), respectively. Differentially labeled test and reference 
samples were mixed with Agilent control targets before being hybridized onto the 
oligomicroarrays for 17 hr at 60°C in a rotating oven. The fluorescence intensities of the 
targets were detected using a laser confocal scanner (Agilent Technologies), and the 
resulting images were processed using the Feature Extraction Software, version 9.1 
(Agilent Technologies). 
 
2.7. Quantitative real-time RT-PCR   
   Two-step real-time RT-PCR was performed using a StepOne Real-Time PCR System 
(Applied Biosystems). cDNA was synthesized using a High-capacity cDNA Reverse 
Transcription kit (Applied Biosystems). TaqMan Gene Expression Assays (Applied 
Biosystems) were used to measure the mRNA levels of MYL6B (Assay ID: 
Hs00365997_g1), MET (assay ID: Hs01565580_m1), NUP107 (Assay ID: 
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Hs00914852_m1), HSPA4 (Assay ID: Hs00382884_m1), and SCOC (Assay ID: 
Hs00261486_m1). mRNA levels were expressed as n-fold differences relative to G3PDH 
(internal standard) and their levels in normal testis tissues (calibrator). PCR was 
performed using TaqMan PCR Master Mix (Applied Biosystems), and the thermal 
cycling conditions involved initial denaturation at 95°C for 10 min followed by 50 cycles 
of 95°C for 15 sec and 60°C for 1 min. The parameter Ct was defined as the threshold 
cycle number in which the fluorescence generated by the cleavage of the probe passed 
above the baseline. The target mRNA was quantified by measuring its Ct value, and 
transcripts of G3PDH were quantified as an endogenous RNA control using TaqMan 
human G3PDH control reagents (Applied Biosystems). 
 
3. Results 
3.1. Autologous serum screening of cDNA library 
   A cDNA expression library of 1.2 x 106 clones was prepared from the OU-LU-11 lung 
adenocarcinoma cell line. Immunoscreening 1.6 x 105 clones with autologous patient 
serum yielded a total of 21 positive clones. The nucleotide sequences of the cDNA inserts 
identified 19 different genes, which were designated as OY-LC-17 to OY-LC-35 (Table 1). 
OY-LC-19 was found in 3 overlapping clones. OY-LC-25 and OY-LC-28 were found in 2 
overlapping clones. The others were all isolated from single clones.   
   A cDNA expression library of 3 x 106 clones was prepared from the OU-LU-17 lung 
adenocarcinoma cell line. Immunoscreening 2 x 105 clones with autologous patient serum 
yielded a total of 20 positive clones. The nucleotide sequences of the cDNA inserts 
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identified 9 different genes, which were designated as OY-LC-36 to OY-LC-44 (Table 2). 
OY-LC-36, nucleoporin 107 (NUP107), was the most frequently isolated antigens, being 
found in 5 overlapping clones. OY-LC-37, chromosome 21 open reading frame 58 
(C21orf58), was the second most frequently isolated, being found in 4 overlapping 
clones.   
   All genes showed universal expression in adult normal tissues in the UniGene 
database. 
 
3.2. Reactivity of allogeneic sera with SEREX-defined antigens 
   The reactivity of sera from healthy donors and lung cancer patients with the randomly 
selected 17 SEREX-defined antigens was investigated using a phage plaque assay (Fig. 1).  
Allogeneic serum samples were obtained from 27 healthy donors and 32 lung cancer 
patients. As shown in Table 3, all of the 17 antigens screened reacted with a subset of sera 
from both healthy donors and lung cancer patients. 
 
3.3. Gene expression profiles 
   Gene expression analysis was performed on 5 lung adenocarcinoma cell lines 
including those used in SEREX, using cDNA microarray. Of 28 SEREX-defined genes, 5 
genes, MYL6B, MET, NUP107, HSPA4, and SCOC, showed higher expression levels in 
all 5 different cell lines compared with normal lung tissues. MYL6B expression was up 
regulated more than 2-fold in all cell lines (Table 1 and 2). On the other hand, the 
expression of 5 genes, WWC2, TJP2, SAMSN1, C21orf58, and TPT1, was down regulated 
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in all cell lines. 
 
3.4. mRNA expression in normal tissues and tumors 
   To investigate the expression of MYL6B, MET, NUP107, HSPA4, and SCOC mRNA, 
we performed quantitative real-time RT-PCR analysis using the gene specific TaqMan 
probes. As shown in Fig. 2, lower levels of the MYL6B, NUP107, and HSPA4 transcripts 
were observed in normal, nongametogenetic tissues than in the normal testis tissues. On 
the other hand, considerably higher mRNA expression levels of MET and SCOC were 
observed in some normal tissues compared to those in the normal testis tissue. MYL6B, 
NUP107, and HSPA4 mRNA expression was further examined in 5 lung cancers and the 
adjacent normal tissue by quantitative real-time RT-PCR. However, no distinct 
differences in their expression levels were observed between the cancers and adjacent 
normal tissue (Fig. 3). 
 
4. Discussion 
   The 28 antigens identified by our SEREX analysis of 2 lung adenocarcinoma cell lines 
represented a diverse set of proteins. Twenty-five of these antigens were products of 
known genes, and 3 represented novel gene products. 
   Of the SEREX-defined genes, 5, MYL6B, MET, NUP107, HSPA4, and SCOC, showed 
higher expression when gene expression changes were examined in 5 different 
adenocarcinoma cell lines, including those used in SEREX, and compared with those in 
normal lung tissues by cDNA microarray analysis. Using quantitative real-time RT-PCR 
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analysis, we found that the expression levels of MYL6B, NUP107, and HSPA4 mRNA 
were reduced in normal tissues compared to those in normal testis tissue. Although no 
significant differences in their expression were detected between the lung cancer tissue 
and the adjacent normal tissue in the 5 patients examined, one patient showed higher 
expression levels of all 3 genes in their cancer tissue than those in adjacent normal tissue. 
In 5 genes, MYL6B and SCOC were not reported at SEREX database (Table 1 and 2). 
MYL6B encodes a myosin alkali light chain expressed in both skeletal muscle and in 
non-muscle tissue. MYL6B revealed considerably lower expression levels in adult normal 
tissues compared to normal testis, and showed higher expression in 2 of 5 lung cancers 
examined. One of positive lung cancer was adenocarcinoma and the other was squamous 
cell carcinoma.  
   Serological analysis for antigens was performed on the basis of their reactivity with 
sera from healthy donors and lung cancer patients. All examined antigens were reacted 
with sera from a subset of healthy donors and lung cancer patients by phage plaque assay. 
No antigens showed a cancer-restricted recognition pattern. Although, serum reactivity 
was not analyzed against MYL6B by phage plaque assay. The immunogenicity MYL6B 
will be tested for IgG antibody in large number of lung cancer patients by ELISA using 
recombinant protein. Autoantibodies to known normal tissue autoantigens or antibodies 
elicited by antigens related to necrotic tumor products are often found in serum. Although, 
a significant proportion of the SEREX antigens are autoantigens of this kind, mutated 
products might also be present in tumor cells, which can elicit antibodies that cross-react 
with their corresponding non-mutated counterparts in normal cells [8]. 
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   In this study, NUP107 was the most frequently isolated antigen (5 of 41 clones).  
Nup107 is a member of the nucleoporin family. It is located on the nuclear rim and is an 
essential component of the nuclear pore complex. The conserved Nup107-160 complex 
plays a crucial role in organizing nuclear pore complex assembly in the post-mitotic event 
and in the interphase nuclei [21-23]. Some nuclear pore complex proteins have 
demonstrated a relationship with tumor aggressiveness and tumorigenesis. Nup88 
overexpression is closely associated with increased aggressiveness of colorectal cancer 
[24], malignant melanoma [25], and breast cancer [26]. The Nup98 gene is fused to at 
least 15 different partner genes by chromosomal translocation in a wide spectrum of 
hematologic malignancies, including myeloid leukemia, myelogenous leukemia, 
precursor-T lymphoblastic lymphoma/leukemia and myelodysplastic syndromes [27-31]. 
   Previously, we identified a CT antigen, XAGE-1, in lung adenocarcinoma by SEREX 
analysis [18]. In the XAGE-1 transcript, XAGE-1b was the dominant antibody 
production in lung adenocarcinoma patients. Around 10% of lung adenocarcinoma 
patients showed antibody responses [19]. In antibody positive patients, strong CD4 T cell 
responses against XAGE-1 were also elicited [32]. CT antigens have become promising 
target for diagnosis and immunotherapy for patients with various tumors. However, the 
expression frequency of tumor antigens, including CT antigens is in a range between 5% 
and 40% depending on the cancer type, and expression is heterogeneous with frequent 
antigen loss. The development of polyvalent diagnostic marker and cancer vaccine 
containing epitopes derived from different tumor antigens could overcome the 
disadvantage of these tumor antigen characteristics. Taken together, this SEREX study 
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identified new antigens and added to the growing list of lung cancer antigens, which may 
aid the development of diagnostic and immunotherapeutic reagents for patients with lung 
cancer. 
 
Conflict of Interest Statement 
   All authors disclosed none financial and personal relationships with other people or 
organizations that could inappropriately influence their work. 
 
Acknowledgments 
   The authors thank Mr. H. Okamoto, Mr. T. Iwasa, and Mr. Y. Isomoto (Central 
Research Laboratory, Okayama University Medical School) for performing the DNA 
sequencing and cDNA microarray analysis. This work was supported in part by a 
Grant-in Aid for Scientific Research (C) from the Japan Society for the Promotion of 
Science.  
 14 
References 
[1] A.J. Alberg, J.M. Samet, Epidemiology of lung cancer, Chest. 123 (2003) 21S-49S 
[2] L.E. Bröker, G. Giaccone, The role of new agents in the treatment of non-small cell 
lung cancer, Eur. J. Cancer. 38 (2002) 2347-2361 
[3] U. Sahin, O. Türeci, H. Schmitt, B. Cochlovius, T. Johannes, R. Schmits, F. Stenner, 
G. Luo, I. Schobert, M. Pfreundschuh, Human neoplasms elicit multiple specific 
immune responses in the autologous host, Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 
11810-11813 
[5] Y. T. Chen, Identification of human tumor antigens by serological expression cloning: 
an online review on SEREX, Cancer. Immun. [updated 2004 Mar 10; cited 2004 Apr 1] 
(2004) 
[6] Y.T. Chen, M.J. Scanlan, U. Sahin, O. Türeci, A.O. Güre, S. Tsang, B. Williamson, E. 
Stockert, M. Pfreundschuh, L.J. Old, A testicular antigen aberrantly expressed in human 
cancers detected by autologous antibody screening, Proc. Natl. Acad. Sci. U. S. A. 94 
(1997) 1914-1918 
[7] O. Türeci, U. Sahin, C. Zwick, M. Koslowski, G. Seitz, M. Pfreundschuh, 
Identification of a meiosis-specific protein as a member of the class of cancer/testis 
antigens, Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 5211-5216 
[8] M.J. Scanlan, Y.T. Chen, B. Williamson, A.O. Güre, E. Stockert, J.D. Gordan, O. 
Türeci, U. Sahin, M. Pfreundschuh, L.J. Old, Characterization of human colon cancer 
antigens recognized by autologous antibodies, Int. J. Cancer. 76 (1998) 652-658 
[9] N. Brass, A. Rácz, C. Bauer, D. Heckel, G. Sybrecht, E. Meese, Role of amplified 
 15 
genes in the production of autoantibodies, Blood. 93 (1999) 2158-2166 
[10] O. Türeci, U. Sahin, E. Vollmar, S. Siemer, E. Göttert, G. Seitz, A.K. Parkkila, G.N. 
Shah, J.H. Grubb, M. Pfreundschuh, W.S. Sly, Human carbonic anhydrase XII: cDNA 
cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is 
overexpressed in some renal cell cancers, Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 
7608-7613 
[11] M.J. Scanlan, J.D. Gordan, B. Williamson, E. Stockert, N.H. Bander, V. Jongeneel, 
A.O. Güre, D. Jäger, E. Jäger, A. Knuth, Y.T. Chen, L.J. Old, Antigens recognized by 
autologous antibody in patients with renal-cell carcinoma, Int. J. Cancer. 83 (1999) 
456-464 
[12] D. Jäger, E. Stockert, M.J. Scanlan, A.O. Güre, E. Jäger, A. Knuth, L.J. Old, Y.T. 
Chen, Cancer-testis antigens and ING1 tumor suppressor gene product are breast cancer 
antigens: characterization of tissue-specific ING1 transcripts and a homologue gene, 
Cancer. Res. 59 (1999) 6197-6204 
[13] O. Türeci, U. Sahin, M. Pfreundschuh, Serological analysis of human tumor 
antigens: molecular definition and implications, Mol. Med. Today. 3 (1997) 342-349 
[14] A.O. Güre, N.K. Altorki, E. Stockert, M.J. Scanlan, L.J. Old, Y.T. Chen, Human 
lung cancer antigens recognized by autologous antibodies: definition of a novel cDNA 
derived from the tumor suppressor gene locus on chromosome 3p21.3, Cancer. Res. 58 
(1998) 1034-1041 
[15] A.O. Güre, E. Stockert, M.J. Scanlan, R.S. Keresztes, D. Jäger, N.K. Altorki, L.J. 
Old, Y.T. Chen, Serological identification of embryonic neural proteins as highly 
 16 
immunogenic tumor antigens in small cell lung cancer, Proc. Natl. Acad. Sci. U. S. A. 
97 (2000) 4198-4203 
[16] I. Diesinger, C. Bauer, N. Brass, H.J. Schaefers, N. Comtesse, G. Sybrecht, E. Meese, 
Toward a more complete recognition of immunoreactive antigens in squamous cell lung 
carcinoma, Int. J. Cancer. 102 (2002) 372-378 
[17] S. Park, Y. Lim, D. Lee, B. Cho, Y.J. Bang, S. Sung, H.Y. Kim, D.K. Kim, Y.S. Lee, 
Y. Song, D.I. Jeoung, Identification and characterization of a novel cancer/testis antigen 
gene CAGE-1, Biochim. Biophys. Acta. 1625 (2003) 173-182 
[18] A.M. Ali Eldib, T. Ono, M. Shimono, M. Kaneko, K. Nakagawa, R. Tanaka, Y. 
Noguchi, E. Nakayama, Immunoscreening of a cDNA library from a lung cancer cell 
line using autologous patient serum: Identification of XAGE-1b as a dominant antigen 
and its immunogenicity in lung adenocarcinoma, Int. J. Cancer. 108 (2004) 558-563 
[19] K. Nakagawa, Y. Noguchi, A. Uenaka, S. Sato, H. Okumura, M. Tanaka, M. 
Shimono, A.M. Ali Eldib, T. Ono, N. Ohara, T. Yoshino, K. Yamashita, T. Tsunoda, M. 
Aoe, N. Shimizu, E. Nakayama, XAGE-1 expression in non-small cell lung cancer and 
antibody response in patients, Clin. Cancer. Res. 11 (2005) 5496-5503 
[20] S. Domae, Y. Nakamura, Y. Nakamura, A. Uenaka, H. Wada, M. Nakata, M. Oka, K. 
Kishimoto, G. Tsukamoto, Y. Yoshihama, J. Matsuoka, A. Gochi, S. Kohno, T. Saika, 
A. Sasaki, E. Nakayama, T. Ono, Identification of CCDC62-2 as a novel cancer/testis 
antigen and its immunogenicity, Int. J. Cancer. 124 (2009) 2347-2352 
[21] T.C. Walther, A. Alves, H. Pickersgill, I. Loïodice, M. Hetzer, V. Galy, B.B. 
Hülsmann, T. Köcher, M. Wilm, T. Allen, I.W. Mattaj, V. Doye, The conserved 
 17 
Nup107-160 complex is critical for nuclear pore complex assembly, Cell. 113 (2003) 
195-206 
[22] I. Loïodice, A. Alves, G. Rabut, M. Van Overbeek, J. Ellenberg, J.B. Sibarita, V. 
Doye, The entire Nup107-160 complex, including three new members, is targeted as 
one entity to kinetochores in mitosis, Mol. Biol. Cell. 15 (2004) 3333-3344 
[23] C.M. Doucet, J.A. Talamas, M.W. Hetzer, Cell cycle-dependent differences in 
nuclear pore complex assembly in metazoa, Cell. 141 (2010) 1030-1041 
[24] A. Emterling, J. Skoglund, G. Arbman, J. Schneider, S. Evertsson, J. Carstensen, H. 
Zhang, X.F. Sun, Clinicopathological significance of Nup88 expression in patients with 
colorectal cancer, Oncology. 64 (2003) 361-369 
[25] H. Zhang, J. Schneider, I. Rosdahl, Expression of p16, p27, p53, p73 and Nup88 
proteins in matched primary and metastatic melanoma cells, Int. J. Oncol. 21 (2002) 
43-48 
[26] D. Agudo, F. Gómez-Esquer, F. Martínez-Arribas, M.J. Núñez-Villar, M. Pollán, J. 
Schneider, Nup88 mRNA overexpression is associated with high aggressiveness of 
breast cancer, Int. J. Cancer. 109 (2004) 717-720 
[27] J. Borrow, A.M. Shearman, V.P. Stanton, R. Becher, T. Collins, A.J. Williams, I. 
Dubé, F. Katz, Y.L. Kwong, C. Morris, K. Ohyashiki, K. Toyama, J. Rowley, D.E. 
Housman, The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the 
genes for nucleoporin NUP98 and class I homeoprotein HOXA9, Nat. Genet. 12 (1996) 
159-167 
[28] T. Nakamura, Y. Yamazaki, Y. Hatano, I. Miura, NUP98 is fused to PMX1 
 18 
homeobox gene in human acute myelogenous leukemia with chromosome translocation 
t(1;11)(q23;p15), Blood. 94 (1999) 741-747 
[29] H.G. Ahuja, C.A. Felix, P.D. Aplan, The t(11;20)(p15;q11) chromosomal 
translocation associated with therapy-related myelodysplastic syndrome results in an 
NUP98-TOP1 fusion, Blood. 94 (1999) 3258-3261 
[30] T. Taketani, T. Taki, N. Shibuya, A. Kikuchi, R. Hanada, Y. Hayashi, Novel 
NUP98-HOXC11 fusion gene resulted from a chromosomal break within exon 1 of 
HOXC11 in acute myeloid leukemia with t(11;12)(p15;q13), Cancer. Res. 62 (2002) 
4571-4574 
[31] I. Lahortiga, J.L. Vizmanos, X. Agirre, I. Vázquez, J.C. Cigudosa, M.J. Larrayoz, F. 
Sala, A. Gorosquieta, K. Perez-Equiza, M.J. Calasanz, M.D. Odero, NUP98 is fused to 
adducin 3 in a patient with T-cell acute lymphoblastic leukemia and myeloid markers, 
with a new translocation t(10;11)(q25;p15), Cancer. Res. 63 (2003) 3079-3083 
[32] M. Shimono, A. Uenaka, Y. Noguchi, S. Sato, H. Okumura, K. Nakagawa, K. Kiura, 
M. Tanimoto, E. Nakayama, Identification of DR9-restricted XAGE antigen on lung 
adenocarcinoma recognized by autologous CD4 T-cells, Int. J. Oncol. 30 (2007) 
835-840 
 
 19 
Figure legends 
Figure 1. Phage plaque assay. Seventeen different bacterial suspensions (100 l) each 
containing cloned phages (1, OY-LC-17; 2, -19; 3, -23; 4, -25; 5, -28; 6, -31; 7, -32; 8. -35; 
9. -36; 10, -37; 11, -38; 12 -39; 13, -40; 14, -41; 15, -42; 16, -43; 17, -44; and T, negative 
control) were plated onto 140 mm diameter NZY agar dishes and tested for serum 
reactivity. Serum from healthy donor was used in this panel.  
 
Figure 2. Quantitative real-time RT-PCR analysis of MYL6B, NUP107, HSPA4, MET, and 
SCOC mRNA in adult normal tissues. Relative expression to testis was indicated.  
 
Figure 3. Quantitative real-time RT-PCR analysis of MYL6B, NUP107, and HSPA4 
mRNA in 5 lung cancers and the adjacent normal tissues. T and N denote lung cancer and 
normal tissue, respectively. The mRNA expression levels of the cancer tissues were 
normalized to those of the respective adjacent normal tissues. 
 
 
 
 
 
Table 1. SEREX-defined genes identified by screening of a lung adenocarcinoma cell line OU-LU-11 by autologous serum
No. of
SEREX
Dadabase        cDNA microarray (fold change)
 2
Antigen clones Identity/similarities search1 OU-LU-6 -11 -14 -17 -26
OY-LC-17 1/21 ISYI splicing factor homolog (S. cerevisiae) (ISYI) 0 1.61 2.56 1.51 2.37 0.71
OY-LC-18 1/21 Chromosome 9 open reading frame 23 (C9orf23) 1 1.16 0.64 1.85 1.21 1.82
OY-LC-19 3/21 Drebrin-like (DBNL), transcript variant 2 2 0.96 1.43 1.77 2.67 2.90
OY-LC-20 1/21 MORC family (W-type zinc finger 2) (MORC2) 0 1.63 0.90 2.04 1.42 1.87
OY-LC-21 1/21 Cytospin A (CYTSA) 0 - 0.59 - 0.48 -
OY-LC-22 1/21 WW, C2 and coiled-coli domain containing 2 (WWC2) 0 0.79 0.66 0.46 0.15 0.18
OY-LC-23 1/21 SAR1 gene homolog A (S. cerevisiae) (SAR1A) 0 1.78 5.24 1.12 3.11 0.95
OY-LC-24 1/21 Myosin, light polypeptide 6B, alkali, smooth muscle and non-muscle
(MYL6B)
0 2.13 2.19 2.82 2.59 2.72
OY-LC-25 2/21 Polymerase (DNA directed), delta 2, regulatory subunit 50kDa (POLD2) 0 1.02 0.72 1.62 1.75 1.69
OY-LC-26 1/21 Utropin (UTRN) 0 0.78 0.94 0.46 0.54 1.27
OY-LC-27 1/21 Meckel syndrome, type 1 (MKS1) 0 1.58 0.68 0.98 1.69 2.35
OY-LC-28 2/21 Serologically defined colon cancer antigen 8 (SDCCAG8) 4 3.03 0.91 1.90 1.73 2.11
OY-LC-29 1/21 SWAP 70 protein (SWAP70) 16 1.25 2.15 1.28 0.86 0.90
OY-LC-30 1/21 Ubiquitin conjugating enzyme E2I (UBC9 homolog, yeast) (UBE2I) 0 1.72 0.93 2.65 1.98 2.50
OY-LC-31 1/21 Tight junction protein 2 (zona occludens 2 (TJP2), transcript variant 1 0 0.82 0.93 0.88 0.32 0.74
OY-LC-32 1/21 Multi PDZ domain protein (MPDZ) 0 1.43 1.34 0.47 1.02 0.62
OY-LC-33 1/21 Met proto-oncogene (hepatocyte growth factor receptor) (MET) 0 5.96 2.70 1.77 1.47 1.61
OY-LC-34 1/21 Ring finger protein, LIM domain interacting (RLIM), transcript variant 1 0 1.26 1.93 1.03 1.76 1.00
OY-LC-35 1/21 SAM domain, SH3 domain and nuclear localization signals 1 (SAMSN1) 0 0.14 0.88 0.19 0.18 0.20
1Number of clones reported at SEREX database (http://ludwig-sun5.unil.ch/CancerImmunomeDB/)
2Gene expressions in 5 adenocarcinoma cell lines were compared with normanl lung tissues by cDNA microarray analysis.
Table(s)
Table 2. SEREX-defined genes identified by screening of a lung adenocarcinoma cell line OU-LU-17 by autologous serum
No. of
SEREX
Dadabase         cDNA microarray (fold change) 2
Antigen clones Identity/similarities search1 OU-LU-6 -11 -14 -17 -26
OY-LC-36 5/20 Nucleoporin 107 (NUP107) 1 1.63 1.70 3.47 4.23 1.59
OY-LC-37 4/21 Chromosome 21 open reading frame 58 (C21orf58) 0 0.28 1.01 0.54 0.48 0.72
OY-LC-38 3/20 Unknown 0 - - -   - -
OY-LC-39 2/20 SEC63 homolog (S. cervisiae) (SEC63) 0 4.97 1.11 2.82 1.85 2.05
OY-LC-40 2/20 Tumor protein, translationally-controlled 1 (TPT1) 3 0.64 0.58 0.81 0.41 0.44
OY-LC-41 1/20 Heat shock 70kDa protein 4 (HSPA4) 6 2.33 1.53 2.47 1.49 2.72
OY-LC-42 1/20 Baculoviral IAP repeat-containing 2 (BIRC2) 3 1.89 1.07 1.02 0.75 0.69
OY-LC-43 1/20 Ribosomal protein S15A (RPS15A) 1 1.73 0.25 2.24 1.31 1.05
OY-LC-44 1/20 Short-coiled-coil protein (SCOC) 0 3.59 1.29 4.23 2.00 3.09
1Number of clones reported at SEREX database (http://ludwig-sun5.unil.ch/CancerImmunomeDB/)
2Gene expressions in 5 adenocarcinoma cell lines were compared with normanl lung tissues by cDNA microarray analysis.
Table(s)
Antigen Healthy donors Lung cancer patients
OY-LC-17 4/10 3/10
OY-LC-19 6/10 3/10
OY-LC-23 2/10 2/10
OY-LC-25 2/10 1/10
OY-LC-28 3/10 2/10
OY-LC-31 3/10 3/10
OY-LC-32 1/10 1/10
OY-LC-35 5/10 2/32
OY-LC-36 4/27 4/32
OY-LC-37 6/27 3/32
OY-LC-38 5/27 3/32
OY-LC-39 4/27 4/32
OY-LC-40 11/27 2/32
OY-LC-41 8/27 1/32
OY-LC-42 6/27 1/32
OY-LC-43 9/27 1/32
OY-LC-44 6/27 2/32
Sera
Table 3. Reactivity of sera from healthy donors and lung cancer
patients with SEREX-defined antigens
Table(s)
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